Drugs / MCS-2
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT01003171 | Aug 2011 → Dec 2012 | — | Health Ever Bio-Tech Co., Ltd. | Unknown | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT01002222 | Jan 2011 → Feb 2014 | benign prostatic hyperplasia | Health Ever Bio-Tech Co., Ltd. | Completed | No outcome recorded |
| Phase 3 | NCT01002274 | Aug 2010 → Jun 2014 | benign prostatic hyperplasia | Health Ever Bio-Tech Co., Ltd. | Completed | No outcome recorded |
| Comparator or background therapy2 trials | ||||||
| Phase 2/3 | NCT01002417 Comparator | Jul 2010 → Feb 2014 | benign prostatic hyperplasia | Health Ever Bio-Tech Co., Ltd. | Completed | No outcome recorded |
| Phase 3 | NCT01002664 Comparator | May 2010 → Jun 2014 | benign prostatic hyperplasia | Health Ever Bio-Tech Co., Ltd. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MCS-2 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01002222 ↗ |
| Route | Oral | “One MCS-2 15 mg soft-gel capsule plus one matching placebo capsule, oral daily for 12 weeks.” NCT01002417 ↗ |